Evolution of randomized, controlled studies of medical therapy in chronic thromboembolic pulmonary hypertension.

In the same study, a nonsignificant trend toward improvement with bosentan, compared with placebo, in WHO FC was observed (improvement in 15% of bosentan-treated and 11% of placebo-treated patients at Week 16).

also in 5,406 other papers